[Transplacental passage of the pyrimethamine-sulfadoxine combination in the prenatal treatment of congenital toxoplasmosis].
Dorangeon
P
P
Fay
R
R
Marx-Chemla
C
C
Leroux
B
B
Harika
G
G
Dupouy
D
D
Quereux
C
C
Choisy
H
H
Pinon
J M
JM
Wahl
P
P
D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D011247:Pregnancy; D011739:Pyrimethamine / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy*
D013413:Sulfadoxine; D011739:Pyrimethamine
Passage transplacentaire de l'association pyriméthamine-sulfadoxine lors du traitement anténatal de la toxoplasmose congénitale.